Compare Lucid Group Inc (LCID) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lucid Group Inc vs Smith & Nephew plc — how do they compare? Lucid Group Inc trades at $3.78 (market cap $1.51B), while Smith & Nephew plc trades at $27.22 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 7.4× Lucid Group Inc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Lucid Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lucid Group Inc for 45 Days and Smith & Nephew plc for 121 Days on average.
| LCID | SNN | |
|---|---|---|
Market Cap | $1.51B | $11.10B |
Volume | 12,333,745 | 1,051,703 |
Sector | Consumer Cyclical | Health |
52-Week High | $21.92 | $37.17 |
52-Week Low | $3.82 | $26.42 |
Typical Hold Time | 45 Days | 121 Days |
Enterprise Value | $4.40B | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lucid Group (LCID) trades at $3.785, down 2.7% with a bearish technical outlook. The company shows concerning fundamentals with negative profit margins (-249.21% net income margin) and consistent earnings misses. Recent news highlights operational challenges including delayed Cosmos SUV launch and aggressive cost-cutting targets of $1.4 billion for 2026. Cash flow remains negative at -$566 million, though strategic partnerships with Bolt for autonomous vehicles provide some growth potential.
LCID faces significant execution risks amid high cash burn and competitive EV market pressures. Analyst consensus is cautious with 67% hold ratings and $7.60 price target suggesting 101% upside potential. The stock presents high-risk speculation for investors betting on successful turnaround execution and partnership developments.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
